SELLAS Life Sciences Group, Inc. Noncash or Part Noncash Acquisition, Intangible Assets Acquired
SELLAS Life Sciences Group, Inc. (SLS) reported Noncash or Part Noncash Acquisition, Intangible Assets Acquired of $0 for the 3-month period ending 2024-03-31, per its 10-Q filed 2024-05-14.
Discontinued › Cash Flow › Operating Activities
us-gaap:NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1 · last filed 2024-05-14
- SELLAS Life Sciences Group, Inc. noncash or part noncash acquisition, intangible assets acquired for the quarter ending 2024-03-31 was $0.00, a 100.00% decline year-over-year.
- SELLAS Life Sciences Group, Inc. noncash or part noncash acquisition, intangible assets acquired for the quarter ending 2023-09-30 was $0.00.
- SELLAS Life Sciences Group, Inc. noncash or part noncash acquisition, intangible assets acquired for the quarter ending 2023-06-30 was -$5.50M.
- SELLAS Life Sciences Group, Inc. noncash or part noncash acquisition, intangible assets acquired for the quarter ending 2023-03-31 was $5.50M.
| Period end | Noncash or Part Noncash Acquisition, Intangible Assets Acquired 3 month | Noncash or Part Noncash Acquisition, Intangible Assets Acquired 6 month | Noncash or Part Noncash Acquisition, Intangible Assets Acquired 9 month |
|---|---|---|---|
| 2024-03-31 | $0.00 10-Q · filed 2024-05-14 | ||
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -$5.50M derived: sum of 2 quarters · filed 2023-11-09 | $0.00 10-Q · filed 2023-11-09 |
| 2023-06-30 | -$5.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $0.00 10-Q · filed 2023-08-10 | |
| 2023-03-31 | $5.50M 10-Q · filed 2024-05-14 | ||
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $5.50M 10-Q · filed 2023-11-09 | |
| 2022-06-30 | $5.50M 10-Q · filed 2023-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |